GC
ALIM

Globeflex Capital’s Alimera Sciences ALIM Stock Holding History

Globeflex Capital’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-28
Closed – – 559
2016
Q4 		$0 Buy
+28
New +$513 ﹤0.01% 548

Other funds holding ALIM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Globeflex Capital's ALIM Position: Q1 2017 in Review

Globeflex Capital sold out of Alimera Sciences (ALIM) in Q1 2017, closing a stake of 28 shares.

Globeflex Capital first reported a position in ALIM in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 39 funds tracked by Wall St. Rank hold ALIM as of Q1 2017.

  • Globeflex Capital reported no remaining Alimera Sciences position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 28 Alimera Sciences shares in Q1 2017.
  • Globeflex Capital first reported a position in Alimera Sciences in Q4 2016 and held it in 1 quarter.
  • Globeflex Capital's Alimera Sciences position peaked at $0 in Q4 2016.
  • 39 funds tracked by Wall St. Rank held Alimera Sciences as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.